Clinical Cancer Drugs


Giulio Francia
The University of Texas
El Paso, TX


Become EABM
Become Reviewer

Most Cited Article

Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?

Volume:4   Issue:2
Pp: 74-81
Manon Launay, Joseph Ciccolini*, Anne Rodallec, Claire Fournel, Florence Duffaud, Sebastien Salas and Bruno Lacarelle
DOI: 10.2174/2212697X04666170531080625

The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer

Volume:4   Issue:1
Pp: 47-58
Jens C. Hahne*, Jorg B. Engel, Arnd Honig, Susanne R. Meyer, Domenico Zito, Andrea Lampis and Nicola Valeri
DOI: 10.2174/2212697X04666170321112629

Intra-arterial Temozolomide, Osmotic Blood-brain Barrier Disruption and Radiotherapy in a Rat F98-Glioma Model

Volume:4   Issue:2
Pp: 135-144
Annie I. Drapeau, Marie-Belle Poirier, Guru-Swamy Madugundu, J. Richard Wagner and David Fortin*
DOI: 10.2174/2212697X04666170727152212

Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World

Volume:4   Issue:2
Pp: 82-92
Antonello Di Paolo*, Marzia Del Re, Elena Arrigoni, Teresa Di Desidero, Eleonora Rofi, Romano Danesi and Guido Bocci
DOI: 10.2174/2212697X04666170817124625